表紙
市場調査レポート

徐放性ドラッグデリバリー市場およびパイプライン見通し

Controlled Release Drug Delivery Market & Pipeline Insight

発行 KuicK Research 商品コード 304894
出版日 ページ情報 英文 830 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
徐放性ドラッグデリバリー市場およびパイプライン見通し Controlled Release Drug Delivery Market & Pipeline Insight
出版日: 2014年05月01日 ページ情報: 英文 830 Pages
概要

徐放性ドラッグデリバリーとは製剤成分と薬剤を予定したとおりの割合で放出することを目的とする材料とを組み合わせたシステムのことを言います。他の種類の標的型ドラッグデリバリーと比較すると、あらかじめ定められた時間にわたって、またあらかじめ定められた割合で薬剤をうまく送達できるため、徐放性ドラッグデリバリーシステムの方がより適切なものであると認められます。このシステムには重要な利点が二つあります。ひとつは一回量の薬剤を頻繁に投与する必要がなく、ゼロ次放出を通じて大きな濃度変動なしに療法上最適な血漿中薬剤濃度を維持できることです。もう一つは薬剤送達の時間を短縮できることで、これによって患者のコンプライアンスを改善でき、また薬の有効性を向上して副作用を減らし、体内への吸収性を上げることができます。社会の高齢化に伴って癌のような特定の病気の発生が増加しており、徐放性のメカニズムを用いた薬剤送達の需要が高まっていることからも、徐放性ドラッグデリバリー市場は今後数年にわたって年率10%の成長率で拡大を続けると予測されます。

当レポートは徐放性ドラッグデリバリー市場と、治験パイプライン上で上市を待つ新薬とを精査したもので、徐放性ドラッグデリバリー市場の現況、市場成長促進要因や市場が抱える課題などの市場ダイナミクス、また今後の市場予測について詳しく分析を加えています。また治験パイプライン上で開発段階にある徐放性薬剤、既に承認、市販に至った薬剤、また開発中止となった薬剤をそれぞれ詳細に取り上げ、市場の将来性を見通すデータを提供しています。さらに当レポートは市場競争環境と主要企業の状況について詳細な分析を加えています。

第1章 徐放性ドラッグデリバリー概要

第2章 徐放性ドラッグデリバリーのメカニズム

第3章 なぜ徐放性ドラッグデリバリーが必要なのか?

第4章 徐放性ドラッグデリバリー市場概要

  • 市場概要
  • 治験パイプライン検証

第5章 徐放性ドラッグデリバリー市場ダイナミクス

  • 市場成長促進要因
  • 課題

第6章 徐放性ドラッグデリバリー市場の将来性

第7章 フェーズ別および対象疾患別に見た徐放性薬剤の治験パイプライン

  • 研究段階
  • 臨床前試験段階
  • 治験段階
  • 臨床試験フェーズI
  • 臨床試験フェーズI/II
  • 臨床試験フェーズII
  • 臨床試験フェーズII/III
  • 臨床試験フェーズIII
  • 承認申請
  • 承認済み

第8章 市販されている徐放性薬剤

第9章 開発が一時中止または全面停止となった徐放性薬剤

  • 開発の報知なし
  • 開発停止
  • 開発一時中止

第10章 市場競争状況

  • Allergan
  • BioAlliance Pharma
  • Collegium Pharmaceutical
  • Controlled Therapeutics (Ferring Pharmaceuticals)
  • Cosmo Pharmaceuticals
  • Egalet
  • Encore Therapeutics
  • Flamel Technologies
  • GlaxoSmithKline
  • iCeutica
  • Novartis
  • Pfizer
目次

Controlled drug delivery refers to a system combining the formulation components and devices with the objective of releasing a drug at a predictable rate. The controlled drug delivery system makes it possible in vivo, irrespective of whether the administration of the drug is done through the injected or non-injected route. A controlled drug delivery is observed to occur when a natural or a synthetic polymer is carefully combined with a drug in a manner which enables the release of the active agent from the material in the pre-specified method.

As compared to other forms of targeted drug delivery, the controlled drug delivery system is considered to be more appropriate as it has been successful in delivering the drug at a predetermined rate, locally or systemically for a predetermined period of time. Two major advantages offered by this system include the maintenance of therapeutically optimum drug concentrations in the plasma without major fluctuations through the zero-order release and the absence of the need for frequent single dose administrations. Other advantages include reduced delivery times, which help in improving patient compliance rate, improved levels of clinical efficacy to reduce the side effects and increased bioavailability.

An increase in the proportion of aged people in a society is directly linked to the rising incidence of some specific diseases like cancer, thus relating to the demand for delivery of drugs through the controlled release mechanism. This coupled with increased research activities have led the pharma companies, to focus more on this space, which has in turn become a major driver of this market, thus reflecting the growing need for this technology. Factors like lower dosages, effective administration of drugs, and easy penetration have together made this system a very popular one among the stakeholders. Thus with these drivers pushing the market, it is expected that the controlled drug delivery market would register a growth rate of 10% in the years to come.

The recent breakthroughs in the controlled oral delivery in the field of water-insoluble drugs and biopharmaceuticals are expected to significantly impact the pharmaceutical and biotechnology industries. Additionally, the continuous improvement in the current delivery technologies like novel excipients, processes, and equipment as new tools formulation which scientists could use to develop oral controlled-release formulations has had a significant influence in decreasing cost and increasing the efficiency.

“Controlled Release Drug Delivery Market & Pipeline Insight” Report Highlights:

  • Controlled Release Drug Delivery Market Overview
  • Controlled Release Drug Delivery Mechanism
  • Clinical Pipeline by Phase & Target Indications
  • Drug Profiles in Report: 451
  • Drug Profile in Active Clinical Phase (Research till Registration): 234
  • Majority of Controlled Release Drug in Phase-II Development: 58
  • Marketed Controlled Release Drugs: 140
  • Suspended & Discontinued Drug Profiles

Table of Contents

1. Introduction to Controlled Release Drug Delivery

2. Controlled Release Drug Delivery Mechanism

3. Why Need for Controlled Release Drug Delivery?

4. Controlled Release Drug Delivery Market Overview

  • 4.1 Market Overview
  • 4.2 Clinical Pipeline Insight

5. Controlled Release Drug Delivery Market Dynamics

  • 5.1 Drivers
  • 5.2 Challenges

6. Controlled Release Drug Delivery Market Future Opportunities

7. Controlled Release Drug Clinical Pipeline by Phase & Target Indications

  • 7.1 Research
  • 7.2 Preclinical
  • 7.3 Clinical
  • 7.4 Phase I
  • 7.5 Phase I/II
  • 7.6 Phase II
  • 7.7 Phase II/III
  • 7.8 Phase III
  • 7.9 Preregistration
  • 7.10 Registered

8. Marketed Controlled Release Drugs

9. Suspended & Discontinued Controlled Release Drug Profiles

  • 9.1 No Development Reported
  • 9.2 Discontinued
  • 9.3 Suspended

10. Competitive Landscape

  • 10.1 Allergan
  • 10.2 BioAlliance Pharma
  • 10.3 Collegium Pharmaceutical
  • 10.4 Controlled Therapeutics (Ferring Pharmaceuticals)
  • 10.5 Cosmo Pharmaceuticals
  • 10.6 Egalet
  • 10.7 Encore Therapeutics
  • 10.8 Flamel Technologies
  • 10.9 GlaxoSmithKline
  • 10.10 iCeutica
  • 10.11 Novartis
  • 10.12 Pfizer

List of Figures

  • Figure 1-1: Oral Drug Delivery Segments
  • Figure 2-1: Types of Controlled Drug Delivery Systems
  • Figure 2-2: Rate Programmed Drug Delivery Systems
  • Figure 2-3: Activation-Modulated Drug Delivery System
  • Figure 4-1: Composition of Drug Delivery Market
  • Figure 4-2: Global Market for Oral Drug Delivery (US$ Billion), 2013 & 2018
  • Figure 4-3: Controlled Release Drug Delivery Clinical Pipeline by Phase (%), 2014
  • Figure 4-4: Controlled Release Drug Delivery Clinical Pipeline by Phase (Number), 2014
  • Figure 4-5: No Development in Controlled Release Drug Delivery Clinical Pipeline by Phase (%), 2014
  • Figure 4-6: No Development in Controlled Release Drug Delivery Clinical Pipeline by Phase (Number), 2014
  • Figure 4-7: Discontinued Controlled Release Drug Delivery Clinical Pipeline by Phase (%), 2014
  • Figure 4-8: Discontinued Controlled Release Drug Delivery Clinical Pipeline by Phase (number), 2014
  • Figure 4-9: Suspended Controlled Release Drug Delivery Clinical Pipeline by Phase (%), 2014
  • Figure 4-10: Suspended Controlled Release Drug Delivery Clinical Pipeline by Phase (Number), 2014
Back to Top